Dr Shahram Ehteshami, MD | |
432 Lexington St Ste C, Delano, CA 93215-3696 | |
(661) 725-3122 | |
(661) 721-2629 |
Full Name | Dr Shahram Ehteshami |
---|---|
Gender | Male |
Speciality | Neurological Surgery |
Location | 432 Lexington St Ste C, Delano, California |
Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
Identifier | Type | State | Issuer |
---|---|---|---|
1699758599 | NPI | - | NPPES |
00A463241 | Medicaid | CA |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
207T00000X | Neurological Surgery | A46324 (California) | Primary |
Mailing Address | Practice Location Address |
---|---|
Dr Shahram Ehteshami, MD Po Box 1228, Bakersfield, CA 93302-1228 Ph: (661) 326-8002 | Dr Shahram Ehteshami, MD 432 Lexington St Ste C, Delano, CA 93215-3696 Ph: (661) 725-3122 |
News Archive
Researchers at Huntsman Cancer Institute at the University of Utah have found that defects in how cells are squeezed out of overcrowded tissue to die, a process called extrusion, may be a mechanism by which pancreatic cancer begins. From these findings, they may have identified an effective way to reverse the defective extrusion's effects without destroying normal tissues nearby.
ViroPharma Incorporated has announced that the U.S. Food and Drug Administration (FDA) has granted priority review for Cinryze C1 Inhibitor (human) as a treatment for acute attacks of Hereditary Angioedema (HAE).
Bioject Medical Technologies Inc., a leading developer of needle-free injection therapy systems, today announced that on December 18, 2009, it completed a Series G Preferred Stock financing with each of Life Sciences Opportunities Fund II, L.P., Life Sciences Opportunities Fund (Institutional) II, L.P. (collectively, the "LOF"), and Edward Flynn for the purchase of an aggregate of 92,448 shares of its Series G Convertible Preferred Stock at a price of $13.00 per share.
Pfizer Inc. today announced, at the request of the U.S. Food and Drug Administration (FDA), the suspension of the chronic low back pain and painful diabetic peripheral neuropathy studies in the clinical program for the investigational compound tanezumab. Investigation of the compound continues in some areas of high unmet medical need, including cancer pain.
› Verified 9 days ago